MyAmyloidosisTeam

Great question! To clarify the term — a "depleter" medication works by reducing the amount of TTR protein the liver produces, which helps prevent amyloid deposits from forming in the first place.

Currently, there are already approved depleter-style medications (called gene silencers) that work this way for hereditary ATTR Show Full Answer

Great question! To clarify the term — a "depleter" medication works by reducing the amount of TTR protein the liver produces, which helps prevent amyloid deposits from forming in the first place.

Currently, there are already approved depleter-style medications (called gene silencers) that work this way for hereditary ATTR (hATTR). These include:

- Patisiran (Onpattro)
- Vutrisiran (Amvuttra) — recently also approved for wild-type ATTR cardiomyopathy in 2025
- Eplontersen (Wainua)

Vutrisiran is a significant development, as it became the first gene-silencing depleter approved for wild-type ATTR affecting the heart in 2025. Research in this area is actively continuing, and more options are expected to emerge from clinical trials in the coming years. It's worth talking to a specialist about whether vutrisiran or any upcoming trials might be a good fit, as the treatment landscape is evolving quickly.

 AI-generated responses are not a substitute for medical advice. These services are not intended to diagnose, treat, or cure any condition or disease. Always ask your doctor about specific health concerns.

Is Cardiac Amyloidosis Curable? 5 Ways To Treat It

5 ATTR Polyneuropathy Treatments and How They Differ